Enlivex (ENLV) Cash from Financing Activities (2013 - 2025)
Enlivex (ENLV) posted quarterly Cash from Financing Activities of $9.8 million for Q4 2025, up 679.7% year-over-year from $1.3 million in Q4 2024, and up 2693.18% quarter-over-quarter from $352000.0 in Q3 2025.
Enlivex (ENLV) Cash from Financing Activities (2013 - 2025) Analysis & Trends
Enlivex's Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $9.8 million for Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 679.7% year-over-year to $9.8 million; the TTM figure through Dec 2025 stood at $10.4 million (up 60.85% YoY), while the FY2025 annual figure was $10.4 million, up 60.85% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $9.8 million, up from $352000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $60.9 million in Q1 2021, with the low at -$3000.0 in Q4 2021.
- The 5-year median for Cash from Financing Activities is $223500.0 (2024), against an average of $4.9 million.
- The sharpest annual moves came in 2021 and 2024: Cash from Financing Activities sank 100.03% in 2021, then soared 10421.43% in 2024.
- Enlivex's Cash from Financing Activities stood at -$3000.0 in 2021, then surged by 1766.67% to $50000.0 in 2022, then fell by 16.0% to $42000.0 in 2023, then jumped by 2902.38% to $1.3 million in 2024, then soared by 679.7% to $9.8 million in 2025.
- Business Quant data shows ENLV's Cash from Financing Activities at $9.8 million in Q4 2025, $352000.0 in Q3 2025, and $197000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | 9.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.83 Mn |
| Dec 31, 2025 | 9.83 Mn |
| Sep 30, 2025 | 352,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 250,000.00 |
| Sep 30, 2024 | 250,000.00 |
| Jun 30, 2024 | 4.42 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Mar 31, 2024 | 524,000.00 |
| Mar 31, 2024 | 524,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Mar 31, 2023 | 318,000.00 |
| Mar 31, 2023 | 318,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Sep 30, 2022 | 50,000.00 |